News on Dynawell International AG from BioPortfolio.com http://www.BioPortfolio.com Consolidated Dynawell International AG news from BioPortfolio.com Wed, 10 Feb 2010 07:44:01 GMT en Treating delirium in a general hospital: a descriptive study of prescribing patterns and outcomeshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039799&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039799&THISHREF=http://c.moreover.com/click/here.pl%3fz2538383149%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039799&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039799&THISHREF=http://c.moreover.com/click/here.pl%3fz2538383149%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: NYC urges some to get mumps vaccinehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039705&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039705&THISHREF=http://c.moreover.com/click/here.pl%3fz2538334004%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039705&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039705&THISHREF=http://c.moreover.com/click/here.pl%3fz2538334004%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comI Stock Analyst: Stocks That Stand Out For Feb. 9th, 2010 Are Feb 08, 2010 - Bergio International, Inc. (OTC Bulletin Board: BRhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038816&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038816&THISHREF=http://c.moreover.com/click/here.pl%3fz2537784070%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038816&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038816&THISHREF=http://c.moreover.com/click/here.pl%3fz2537784070%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Powering Disaster Relief In Haiti: Partnership Provides Electricity To Emergency Medical Teams And Relief Effohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039066&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039066&THISHREF=http://c.moreover.com/click/here.pl%3fz2537904353%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039066&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039066&THISHREF=http://c.moreover.com/click/here.pl%3fz2537904353%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Novartis International AG : Novartis gains exclusive rights to Debio 025, a...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033390&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033390&THISHREF=http://c.moreover.com/click/here.pl%3fz2535175689%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033390&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033390&THISHREF=http://c.moreover.com/click/here.pl%3fz2535175689%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInvestegate: Novartis gains exclusive rights to Debio 025, an antiviral agent ...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033510&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033510&THISHREF=http://c.moreover.com/click/here.pl%3fz2535245064%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033510&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033510&THISHREF=http://c.moreover.com/click/here.pl%3fz2535245064%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: UPDATE: Ratiopharm Shortlist Expected Early Next Week - Sourceshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037351&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037351&THISHREF=http://c.moreover.com/click/here.pl%3fz2537041531%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037351&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037351&THISHREF=http://c.moreover.com/click/here.pl%3fz2537041531%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMorningstar.com: Novartis International AG (CH) - Novartis Gains Exclusive Rights to Debio 025, an Antiviral Agent in Phase IIbhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037066&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037066&THISHREF=http://c.moreover.com/click/here.pl%3fz2536889641%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037066&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037066&THISHREF=http://c.moreover.com/click/here.pl%3fz2536889641%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: UPDATE: Ratiopharm Shortlist Expected Early Next Week - Sourceshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036978&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036978&THISHREF=http://c.moreover.com/click/here.pl%3fz2536852707%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036978&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036978&THISHREF=http://c.moreover.com/click/here.pl%3fz2536852707%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXNews.com: UPDATE: Ratiopharm Shortlist Expected Early Next Week - Sourceshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036806&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036806&THISHREF=http://c.moreover.com/click/here.pl%3fz2536764310%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036806&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036806&THISHREF=http://c.moreover.com/click/here.pl%3fz2536764310%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: UPDATE: Ratiopharm Shortlist Expected Early Next Week - Sourceshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036708&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036708&THISHREF=http://c.moreover.com/click/here.pl%3fz2536715821%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036708&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036708&THISHREF=http://c.moreover.com/click/here.pl%3fz2536715821%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNasdaq: Novartis International AG (CH) - Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIbhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035463&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035463&THISHREF=http://c.moreover.com/click/here.pl%3fz2536252748%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035463&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035463&THISHREF=http://c.moreover.com/click/here.pl%3fz2536252748%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Novartis Gains Exclusive Rights to Debio 025, an Antiviral Agent in Phase IIb Development as Potential First-ihttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034627&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034627&THISHREF=http://c.moreover.com/click/here.pl%3fz2535895040%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034627&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034627&THISHREF=http://c.moreover.com/click/here.pl%3fz2535895040%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033542&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033542&THISHREF=http://c.moreover.com/click/here.pl%3fz2535259086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033542&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033542&THISHREF=http://c.moreover.com/click/here.pl%3fz2535259086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033432&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033432&THISHREF=http://c.moreover.com/click/here.pl%3fz2535198360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033432&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynawell%20International%20AG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033432&THISHREF=http://c.moreover.com/click/here.pl%3fz2535198360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: